Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Idenix Pharmaceuticals, Inc.
Idenix Pharmaceuticals shares plunged 19.78 percent on volume of nearly 6 million shares traded Monday to close at $3.69 a share. The company announced that the U.S. Patent and Trademark Office Patent Trial and Appeal Board has decided against the company in the first phase of the ongoing interference concerning one of the Company’s patent applications and an issued patent owned by Gilead Pharmasset LLC.
Going forward ... (see research report)
Subscribe to News Feeds